Home LiteratureArticle Details
PMID: 16368883 Published · ppublish English Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Blood ·Vol. 107 ·No. 9 ·2006-05-01 ·Pages 3724-6

Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP

Abstract

FLT3 internal tandem duplications (FLT3/ITDs) in the juxtamembrane domain are found in approximately 25% of acute myeloid leukemia (AML) patients, ranging in size from 3 to hundreds of nucleotides. We examined whether the sizes of FLT3/ITDs were associated with clinical outcomes in 151 AML patients enrolled in Southwest Oncology Group studies: S9333 and S9500. FLT3/ITDs were identified in 32% of patients (median ITD size = 39 nucleotides; range, 15-153 nucleotides). The CR rates were 35%, 67%, and 52% for patients with large (>or= 40), small (< 40), and no ITDs, respectively (P = .19). Increasing ITD size was associated with decreasing OS (estimated 5-year OS: large = 13%, small = 26%, and no ITD = 21%, P = .072) and RFS (estimated 5-year RFS: large = 13%, small = 27%, and no ITD = 34%, P = .017). These studies suggest that ITD size may have prognostic significance.

MeSH Terms
Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols/therapeutic use Humans Leukemia, Myeloid, Acute/drug therapy,genetics,mortality Middle Aged Prognosis Protein Structure, Tertiary Survival Rate Tandem Repeat Sequences fms-Like Tyrosine Kinase 3/chemistry,genetics
Chemicals
FLT3 protein, human fms-Like Tyrosine Kinase 3
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Stirewalt Derek L
Fred Hutchinson Cancer Research Center, D5-380, 1100 Fairview Ave N. Seattle, WA 98109, USA. dstirewa@fhcrc.org
Kopecky Kenneth J
Meshinchi Soheil
Engel Julia H
Pogosova-Agadjanyan Era L
Linsley Jeremy
Slovak Marilyn L
Willman Cheryl L
Radich Jerald P
References (23)
23 references, click to expand
  1. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells.
    Br J Haematol. 2000 Feb;108(2):322-30 PMID: 10691863
  2. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.
    Leukemia. 2000 Oct;14(10):1766-76 PMID: 11021752
  3. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Blood. 2000 Dec 1;96(12):3907-14 PMID: 11090077
  4. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.
    Blood. 2001 Jan 1;97(1):89-94 PMID: 11133746
  5. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
    Blood. 2001 Apr 15;97(8):2434-9 PMID: 11290608
  6. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.
    Blood. 2001 Jun 1;97(11):3589-95 PMID: 11369655
  7. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
    Blood. 2001 Sep 15;98(6):1752-9 PMID: 11535508
  8. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.
    Cancer Res. 2001 Oct 1;61(19):7233-9 PMID: 11585760
  9. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Oncogene. 2002 Apr 11;21(16):2555-63 PMID: 11971190
  10. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
    Blood. 2002 Jun 15;99(12):4326-35 PMID: 12036858
  11. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.
    Blood. 2002 Jul 1;100(1):59-66 PMID: 12070009
  12. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
    Blood. 2002 Nov 1;100(9):3423-5 PMID: 12384447
  13. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
    Blood. 2002 Dec 1;100(12):3869-76 PMID: 12393614
  14. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
    Blood. 2002 Dec 15;100(13):4372-80 PMID: 12393388
  15. Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.
    Blood. 2003 Aug 15;102(4):1474-9 PMID: 12702504
  16. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
    Blood. 2003 Oct 1;102(7):2387-94 PMID: 12816873
  17. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.
    Mol Cell. 2004 Jan 30;13(2):169-78 PMID: 14759363
  18. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
    Br J Haematol. 2004 Feb;124(4):481-4 PMID: 14984498
  19. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
    Blood. 2004 Sep 15;104(6):1841-9 PMID: 15166029
  20. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
    Blood. 2004 Nov 1;104(9):2646-54 PMID: 15251987
  21. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
    Blood. 1995 Sep 15;86(6):2329-42 PMID: 7545025
  22. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
    Leukemia. 1998 Sep;12(9):1333-7 PMID: 9737679
  23. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
    Blood. 1999 May 1;93(9):3074-80 PMID: 10216104
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
DOI
10.1182/blood-2005-08-3453
Email
dstirewa@fhcrc.org
Published
2006-05-01
Epub
2005-00-20
Pages
3724-6
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC1895777
Subset
IM
Grants
NCI NIH HHS · CA18029 · United States
NCI NIH HHS · K23 CA92405 · United States
NCI NIH HHS · P01 CA018029 · United States
NCI NIH HHS · CA114563 · United States
NCI NIH HHS · CA32102 · United States
NCI NIH HHS · R01 CA114563 · United States
Corrections
CommentIn
PMID: 16790588
External Links
PubMed source DOI: 10.1182/blood-2005-08-3453 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2